Ilya Pharma Receives Approval from Swedish Regulators to Initiate Phase II Clinical Study of ILP100 Gene Therapy to Treat Difficult Wounds Patients with Diabetes
Link to article in BioPharm International: https://www.biopharminternational.com/view/ilya-pharma-receives-approval-from-swedish-regulators-for-phase-ii-study